Friday, September 12, 2025

Tilray Imports Medical Cannabis to USA to Assist Research on Breast Cancer Related Disorder

Tilray Inc (NASDAQ: TLRY) announced this morning that it has successfully imported medical cannabis from Canada to the United States. The cannabis was imported in support of a clinical trial related to that of breast cancer research.

Specifically, the study is researching the impact that medical cannabis has on individuals that have breast cancer while also suffering from taxane-induced peripheral neuropathy (TIPN). Patients that have TIPN are typically not able to utilize chemotherapy to treat breast cancer to the same extent that those without the disorder are.

Within the study, a randomized group of patients suffering from TIPN will be given a twice daily dosage of active cannabinoids in the form of THC and CBD for eight weeks, while a control group will be given a placebo. It is unclear as to what form of delivery will be used for the cannabinoids within the study.

We’re excited to support this groundbreaking, first-of-its-kind trial seeking to find a new treatment option for TIPN. Tilray is committed to advancing cannabis research through its support of clinical trials around the world as we continue to enhance our understanding of the potential benefits of medical cannabis.

Philippe Lucas, Tilray’s Vice President of Global Patient Research and Access

There are currently no effective treatments for TIPN on the markets, a disorder which effects approximately 67% of women underoing breast cancer treatment. However, early studies conducted on mice with medical cannabis provided positive results in the treatment of TIPN. The research that Tilray is involved within is the first human trial of utilizing medical cannabis to treat the disorder.

Tilray closed yesterday’s session at $22.63 on the Nasdaq.


Information for this briefing was found via Sedar and Tilray. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Hexo To Be Acquired By Tilray For US$56.0 Million

It appears that Sebastian St-Louis’s “billion dollar start-up” has finally been sold. Hexo Corp (TSX:...

Monday, April 10, 2023, 05:26:52 PM

Tilray: Haywood Reiterates Hold Rating, $16.50 Price Target

With the Aphria, Tilray (NASDAQ: TLRY) merger finalized and Aphria shares consolidated earlier this month,...

Wednesday, May 19, 2021, 03:38:00 PM

Tilray Year End: Production Success Overshadowed By Impairments

Tilray Inc. (NASDAQ: TLRY), is off -50% since having published its year end financials after...

Tuesday, March 10, 2020, 09:19:21 AM

Tilray: Haywood Expects Canadian Market Share To Drop In First Quarter

Tilray Inc (TSX: TLRY) (NASDAQ: TLRY) announced that they would be reporting their Fiscal first-quarter...

Thursday, September 30, 2021, 10:38:00 AM

Tilray Q3 FY2025 Results: Shares Slump On 656% Wider Net Loss

Tilray Brands (TSX: TLRY) has reported its financial results for Q3 of fiscal 2025, ending...

Thursday, April 10, 2025, 07:21:00 AM